1Rosen KS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ,double-blind, randomized trialthe Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003,21:3150. 被引量：1
2Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med. 2002, 137(7) : 586. 被引量：1
3Gallowitsoh HJ,Kresnik E, Gasser J, etal. 18F fluorodeoxy glucoee positron - emission of tumor recurrence and metastases in the follow - up of patients with breast carcinoma: A comparison to conventional imaging. Invest Radiol. 2003, 38(5) :250. 被引量：1
4Gayed I, Vu T, Johnson M, et al. Comparison of bone and2-deoxy-^18 F fluoro - D - glucose positron emission tomography in the evalu - atlon of bony metastases in lung caner. Mol Imaging Biol. 2003,5(1):26. 被引量：1
5Uematsu T,Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol. 2005, 184(4):1266. 被引量：1
6Gallowitsch HJ, Kresnik E, Gasser J, etal.^18F fluorodeoxyglucese positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow - up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radinl. 2003, 38(5) : 250. 被引量：1
7Resnick D. Skeletal metastasis. Resnick D. Diagnosis of bone and joint disorders. 4th ed. Philadephia:WB Saunder Co. 2002, 4274. 被引量：1
8Clohisy DR. Metastatic skeletal disease. Filzgarald RH, Kaufer H, Malkani A. Orthopaedies. London: Mosby Inc. 2002, 1078. 被引量：1
4Plawker MW, Fleisher JM, Vapnek EM, Current trends in prostate cancer diagnosis and staging among United States urologists. J Urol,1997,158(5): 1853 被引量：1
6Yahara J, Noguchi M, Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systenic treatment. BJUInt, 2003Sep; 92 (4): 379 被引量：1
7Savelli G, Chiti A, Grasselli G, et al. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res, 2000, 20:1115 被引量：1
8Lissoni P, Vghi M, Ardiffoia A, et al. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to polactin secretion in heavily pretreated metastatic breast cancer. Newroendocrinol Lett. 2001, 22(1):27. 被引量：1
9DiCaprio MR,Friedlaender GE.Malignant bone tumors:limb sparing versus amputation[J].Orthop Surg,2003,11(1):25-37. 被引量：1
10Simon MA,Limb salvage for osleosarcoma[J].J Bone Joint Surg(Am).1988,70(2):307-310. 被引量：1
1Costa L. Bisphosphonates:reducing the risk of skeletal complications from bone metastasis[J].{H}BREAST,2007,(03):S16-S20. 被引量：1
2Chengwang,Jingwang,Han jiang. In vitro study on apoptosis induced by strontium-89in human breast carcinoma cell[J].Biomedicine and Biotechnology,2011,(09):1155-1162. 被引量：1
3Wenjie zhang,Weiwei zhao,Zhiyun jia. Strontium-89therapy for the treatment of huge osseous metastases in prostate carcinoma:A case report[J].Exp Ther Med,2013,(02):608-610. 被引量：1
4Tomasz Skóra,Teresa kowalska,Krystyna zawia. Ef-fectiveness of radioisotope therapy in bone metastases,Based on personal experience[J].Published online,2012,(03):201-205. 被引量：1
5Howard S. Smith,Intikhab mohsin. Painful boney metastases[J].Korean J Pain,2013,(03):223-241. 被引量：1
6Finlay IG,Mason MD,Shelley M. Radioisotopes for the palliation of metastatic bone cancer:a systematic review[J].{H}LANCET ONCOLOGY,2005.40-392. 被引量：1
